Cargando…
Inhibitors of the AAA+ Chaperone p97
It is remarkable that a pathway as ubiquitous as protein quality control can be targeted to treat cancer. Bortezomib, an inhibitor of the proteasome, was first approved by the US Food and Drug Administration (FDA) more than 10 years ago to treat refractory myeloma and later extended to lymphoma. Its...
Autores principales: | Chapman, Eli, Maksim, Nick, de la Cruz, Fabian, La Clair, James J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576884/ https://www.ncbi.nlm.nih.gov/pubmed/25685910 http://dx.doi.org/10.3390/molecules20023027 |
Ejemplares similares
-
Correction: Chapman, E.; et al. Inhibitors of the AAA+ Chaperone p97. Molecules 2015, 20, 3027-3049
por: Chapman, Eli, et al.
Publicado: (2015) -
Mutations in the Human AAA(+) Chaperone p97 and Related Diseases
por: Tang, Wai Kwan, et al.
Publicado: (2016) -
Optimization of Phenyl Indole Inhibitors of the AAA+
ATPase p97
por: LaPorte, Matthew G., et al.
Publicado: (2018) -
The AAA+ ATPase p97, a cellular multitool
por: Stach, Lasse, et al.
Publicado: (2017) -
The AAA-ATPase p97 is essential for outer mitochondrial membrane protein turnover
por: Xu, Shan, et al.
Publicado: (2011)